Background: Timely detection and appropriate treatment of Acute antibody mediated rejection (AMR) would affect long-term survival of allograft. This study was designed to discover non-invasive biomarkers in prediction of response to therapy in AMR patients. Material and methods: in this case- control study, urine samples of 21 biopsy proven AMR patients were were subjected to proteomics with label free quantification. Patients were allocated into two groups of responders and non- responders to treatment. Urine proteins were identified and their expressions were compared in two groups in order to discover potential candidate biomarkers. Results: From 1020 identified proteins, 257 proteins were differentially expressed between groups among them 153 and 104 proteins increased and decreased in non- responder patients respectively. Complement pathway was more active in non-responders than responders and, extracellular matrix proteins were mainly reduced in non-responders. IGFBP-6 were determined as the most sensitive and specific biomarker in prediction of non-responder patients. Conclusion: According to the role of IGFBP-6 in apoptosis induction and tubular damage, up-regulation of this protein could be a good predictor of response to treatment in AMR patients and treatment approach could be determined based on IGFBP_6 changes. Further studies are needed to confirm these findings.